Danna Jennings, MD
Institute for Neurodegenerative Disorders
18
18
14
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+12 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (18)
Showing 10 of 18 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Ken Nedd, M.D.
GAAD Medical Research Institute Inc.
Shared therapeutic areas:
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Robert B Innis, M.D.
National Institute of Mental Health (NIMH)
Shared therapeutic areas:
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
emilie garrido pradalie
APHM
Shared therapeutic areas:
Marie Carmen Valenza, phD
Universidad de Granada
Shared therapeutic areas:
Nieto Luis
Site Coordinator of United Medical Group
Shared therapeutic areas:
Nieto Luis, Master
Site Coordinator of United Medical Group
Shared therapeutic areas:
Eric M Wassermann, M.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Shared therapeutic areas:
Worked with same sponsors:
İsmail ÖZSOY, Assoc. Prof. Dr.
Selcuk University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Konya, Türkiye
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (18)
Showing 18 of 18 trials
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease
A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients
Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease
Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease
Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects
Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease
Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions
Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513
Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC
Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
All 18 trials loaded